Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as the First Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
Penn spinout Apellis Pharmaceuticals, Inc. received U.S. Food and Drug Administration (FDA) approval for their drug SYFOVRE™ (pegcetacoplan injection).
Penn Spinout and I-Corps Graduate Neuroflow Named as 2023 Fire Awards honorees by PHL Inno
The Fire Awards are PHL Inno’s premiere awards program, showcasing the businesses, institutions and individuals driving the Philadelphia region’s innovation scene forward.
Sixth Annual Pennovation Accelerator Pitch Day
ch of the nine Philadelphia-based cohort companies presented a 5-minute pitch to a live audience, followed by questions and feedback from a panel of judges.
Verismo Therapeutics featured in the Philadelphia Business Journal for recent funding
The cell therapy startup recently raised $17 million to advance its lead immunotherapy candidates in a second pre-Series A round of funding.
Penn Engineering and AlphaThera Expand License Agreement
AlphaThera, a startup company co-founded by Andrew Tsourkas, PhD, entered into an expanded license agreement with Penn.
Verismo Therapeutics raises funding and expands partnership with Penn Medicine
Penn spinout company Verismo Therapeutics has successfully raised $7 million in a pre-Series A round led by BRV Capital Management.
Penn Venture Lab receives $10 million gift for health care entrepreneurship
The goal of the gift, donated by Wharton alum Marc Wolpow, is to create an incubator and accelerator for student ventures in health care.
Philadelphia retains top 30 ranking on list of global startup ecosystems in 2023
In 2022, Startup Genome's Global Startup Ecosystem Report ranked Philadelphia as the 27th-best startup ecosystem in the world and number eleven within the U.S.
Penn Startups Win Several PACT Enterprise Awards
viTToria Biotherapeutics and Exyn Technologies, both startups co-founded by Penn faculty, won recent awards from the Philadelphia Alliance for Capital and Technologies.
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 Drug to Target Autoimmune Diseases
Cabaletta Bio received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug CABA-201.